https://www.selleckchem.com/pr....oducts/glesatinib.ht
Western blot analysis showed decreased expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK upon AG01 treatment, as well as inhibition of tumor growth and Ki67 expression in vivo. PGRN/GP88 represents a therapeutic target with companion diagnostics. Blocking PGRN/GP88 with antibody treatment mayprovide novel-targeted solutions in TNBC treatment which could eventually address the issue of toxicity and unresponsiveness associated with SOC. PGRN/GP88 represents a therapeutic target with companion diagnostics. Blocking PG
Like
Comment
Share
